GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference
GeoVax Labs (Nasdaq: GOVX) announced that Chairman & CEO David Dodd will present at NobleCon20, the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference, on December 3, 2024, at 11:30 am ET in Boca Raton, FL. The presentation will be webcasted and available on GeoVax's website, Noble Capital Markets' Conference website, and Channelchek for 90 days.
GeoVax is advancing several clinical programs, including GEO-CM04S1, their next-generation COVID-19 vaccine, which recently received BARDA funding for a 10,000-participant Phase 2b trial. The company is also developing Gedeptin®, an oncolytic solid tumor therapy, with a Phase 2 clinical trial planned for first recurrent head and neck cancer in early 2025.
GeoVax Labs (Nasdaq: GOVX) ha annunciato che il Presidente e CEO David Dodd presenterà al NobleCon20, la ventesima Conferenza Annuale sulle Crescite Emergenti di Noble Capital Markets, il 3 dicembre 2024, alle 11:30 ET a Boca Raton, FL. La presentazione sarà trasmessa in webcast e sarà disponibile sul sito web di GeoVax, sul sito della Conferenza di Noble Capital Markets e su Channelchek per 90 giorni.
GeoVax sta portando avanti diversi programmi clinici, incluso GEO-CM04S1, il loro vaccino di nuova generazione contro il COVID-19, che ha recentemente ricevuto finanziamenti da BARDA per uno studio di Fase 2b con 10.000 partecipanti. L'azienda sta anche sviluppando Gedeptin®, una terapia oncolitica per i tumori solidi, con uno studio clinico di Fase 2 previsto per il primo recidivo di cancro testa-collo all'inizio del 2025.
GeoVax Labs (Nasdaq: GOVX) anunció que el Presidente y CEO David Dodd presentará en NobleCon20, la Vigésima Conferencia Anual de Crecimiento Emergente de Noble Capital Markets, el 3 de diciembre de 2024, a las 11:30 am ET en Boca Raton, FL. La presentación será transmitida por webcast y estará disponible en el sitio web de GeoVax, en el sitio web de la Conferencia de Noble Capital Markets y en Channelchek durante 90 días.
GeoVax está avanzando en varios programas clínicos, incluido GEO-CM04S1, su vacuna de próxima generación contra el COVID-19, que recientemente recibió financiamiento de BARDA para un ensayo de Fase 2b con 10,000 participantes. La empresa también está desarrollando Gedeptin®, una terapia oncolítica para tumores sólidos, con un ensayo clínico de Fase 2 programado para el primer cáncer recurrente de cabeza y cuello a principios de 2025.
GeoVax Labs (Nasdaq: GOVX)는 회장 겸 CEO인 David Dodd가 NobleCon20에서 발표할 것이라고 발표했습니다. 이는 Noble Capital Markets의 제20회 연례 신생 성장 주식 회의로, 2024년 12월 3일 오전 11시 30분 ET에 플로리다주 보카 라톤에서 열립니다. 발표는 웹캐스트로 생중계되며 GeoVax의 웹사이트, Noble Capital Markets의 회의 웹사이트 및 Channelchek에서 90일 동안 이용 가능합니다.
GeoVax는 최근 BARDA로부터 10,000명의 참가자를 대상으로 하는 2b상 시험을 위한 자금을 받았으며, 차세대 COVID-19 백신인 GEO-CM04S1을 포함한 여러 임상 프로그램을 진행하고 있습니다. 이 회사는 또한 Gedeptin®을 개발 중이며, 이는 고형암을 위한 온콜리틱 치료제로 2025년 초에 첫 번째 재발 두경부암에 대해 2상 임상 시험이 계획되어 있습니다.
GeoVax Labs (Nasdaq: GOVX) a annoncé que le Président et CEO David Dodd fera une présentation lors de NobleCon20, la vingtième conférence annuelle sur la croissance émergente de Noble Capital Markets, le 3 décembre 2024, à 11 h 30 ET à Boca Raton, FL. La présentation sera diffusée en webcast et disponible sur le site Web de GeoVax, sur le site de la Conférence de Noble Capital Markets et sur Channelchek pendant 90 jours.
GeoVax progresse dans plusieurs programmes cliniques, y compris GEO-CM04S1, leur vaccin de nouvelle génération contre le COVID-19, qui a récemment reçu un financement de la BARDA pour un essai de Phase 2b avec 10 000 participants. L'entreprise développe également Gedeptin®, une thérapie oncolytique pour les tumeurs solides, avec un essai clinique de Phase 2 prévu pour le premier cancer récurrent de la tête et du cou début 2025.
GeoVax Labs (Nasdaq: GOVX) hat bekannt gegeben, dass der Vorsitzende und CEO David Dodd am NobleCon20, der zwanzigsten Jahrestagung für aufstrebendes Wachstum von Noble Capital Markets, am 3. Dezember 2024 um 11:30 Uhr ET in Boca Raton, FL, präsentiert. Die Präsentation wird als Webcast übertragen und ist 90 Tage lang auf der Website von GeoVax, der Konferenzwebsite von Noble Capital Markets und Channelchek verfügbar.
GeoVax entwickelt mehrere klinische Programme, einschließlich GEO-CM04S1, ihren Impfstoff der nächsten Generation gegen COVID-19, der kürzlich von BARDA Finanzierung für eine Phase-2b-Studie mit 10.000 Teilnehmern erhalten hat. Das Unternehmen entwickelt auch Gedeptin®, eine onkolytische Therapie für solide Tumoren, mit einer geplanten Phase-2-Studie für die erste wiederkehrende Kopf-Hals-Krebsform Anfang 2025.
- None.
- None.
ATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will present at NobleCon20 - the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference taking place December 2-5, 2024 in Boca Raton, FL.
| Presentation Details: | |||
| Speaker: | David Dodd, Chairman & CEO | ||
| Date/Time: | December 3, 2024, 11:30 am ET | ||
| Location: | Florida Atlantic University Executive Education Complex, Boca Raton, FL | ||
| Title: | GeoVax Corporate Update | ||
A high-definition video webcast of the presentation will be available the following day on the Company's website www.geovax.com, and as part of a complete catalog of presentations available at Noble Capital Markets’ Conference website: www.nobleconference.com and on Channelchek: www.channelchek.com the investor portal created by Noble. The webcast will be archived on the company's website, the NobleCon website, and on Channelchek.com for 90 days following the event. Senior GeoVax management will also host one-on-one meetings with registered attendees.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. A Phase 2 clinical trial in first recurrent head and neck cancer, evaluating Gedeptin® combined with an immune checkpoint inhibitor is planned to initiate during the first half of 2025. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
| Company Contact: | Investor Relations Contact: | Media Contact: | ||
| info@geovax.com | austin.murtagh@precisionaq.com | sr@roberts-communications.com | ||
| 678-384-7220 | 212-698-8696 | 202-779-0929 |
FAQ
When will GeoVax (GOVX) present at NobleCon20?
What is GeoVax's (GOVX) main clinical program?
When is GeoVax (GOVX) planning to start the Phase 2 Gedeptin trial?
Where can investors watch GeoVax's (GOVX) NobleCon20 presentation?
